Holen Sie sich die Stockscreener-App
1.10
2.80%
0.03
Handel nachbörslich:
1.15
0.05
+4.55%
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript - MSN
Allogene Therapeutics Q2 2025 Earnings Preview: Revenue Expectations Flat, Earnings Estimates Rise - AInvest
Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha
Allogene's Q2 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - Nasdaq
Allogene outlines clinical milestones with MRD data readout planned for first half 2026 as portfolio advances - MSN
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline - Investing.com
Allogene Therapeutics’ SWOT analysis: stock faces challenges amid promising pipeline By Investing.com - Investing.com South Africa
Allogene Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Allogene Therapeutics Inc. stock chart pattern explained2025 Investor Takeaways & Free Fast Entry Momentum Trade Alerts - Newser
Signal strength of Allogene Therapeutics Inc. stock in tech scannersJuly 2025 Big Picture & High Return Stock Watch Alerts - Newser
ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest
Allogene Therapeutics Q2 2025 Earnings: A Strategic Leap in Cell Therapy Commercialization - AInvest
Transcript : Allogene Therapeutics, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Allogene's Strategic Milestone Progress in 2026 and Its Implications for CAR T Leadership - AInvest
Earnings call transcript: Allogene Therapeutics’ Q2 2025 earnings reveal strategic shifts - Investing.com Nigeria
Allogene Q2 Cash Tops $300 Million - Nasdaq
Allogene Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allogene Narrows Loss in Fiscal Q2 - Nasdaq
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Allogene's CAR T Trials Show Promise in Cancer and Autoimmune Disease, $302M Cash Position - Stock Titan
Will Allogene Therapeutics Inc. benefit from macro trendsMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Allogene Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Allogene Therapeutics Inc. stock trend forecastMarket Stability and Long-Term Growth Outlook - Newser
Volume spikes in Allogene Therapeutics Inc. stock – what they meanDaily Trade Monitor with Pattern Alerts - Newser
Can trapped investors hope for a rebound in Allogene Therapeutics Inc.Smart Trend Analysis With Buy Point Cues - Newser
Allogene Therapeutics shares rise 2.86% after-hours following Sumitomo Pharma's submission for Parkinson's disease treatment. - AInvest
Is Allogene Therapeutics Inc. meeting your algorithmic filter criteriaPre-Market Stock Movement Summary and Review - Newser
Follicular Lymphoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsights | AstraZeneca, InnoCare Pharma, Allogene Therapeutics, HUTCHMED, Sound Bio - Barchart.com
Allogene Therapeutics Schedules Conference Call and Webcast to Discuss Q2 2025 Financial Results on August 13 - Quiver Quantitative
Allogene Therapeutics announces Q2 2025 financial results, conference call on August 13. - AInvest
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update - Stock Titan
How to integrate Allogene Therapeutics Inc. into portfolio analysis toolsFree Breakout Entry Signal Confirmation Tool - Newser
Allogene Therapeutics shares fall 1.36% intraday after Sumitomo Pharma and RACTHERA submit application for Parkinson's disease treatment. - AInvest
What makes Allogene Therapeutics Inc. stock price move sharplyEquity Signal Recap With Long-Term Summary - Newser
JMP Securities Reiterates Market Perform Rating for Allogene Therapeutics Inc. - AInvest
Allogene Therapeutics Maintains Buy Rating Amid Strategic Adjustments and Technological Advancements - AInvest
Patient Dies After Receiving Monoclonal Antibody Lymphodepletion Regimen in LBCL Trial for Allogene’s Cema-Cel - CGTLive®
Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death - insights.citeline.com
Allogene stock maintains Market Perform rating at Citizens JMP after trial adjustment - Investing.com Canada
Allogene stock continues ALPHA3 trial with standard FC regimen after safety event - Investing.com Canada
Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial - BioSpace
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Patient death in Allogene trial - The Pharma Letter
What is Allogene Therapeutics Inc. company’s growth strategyBuild wealth steadily with proven investment strategies - Jammu Links News
What are the technical indicators suggesting about Allogene Therapeutics Inc.High-yield growth strategies - Jammu Links News
When is Allogene Therapeutics Inc. stock expected to show significant growthInvest confidently with market-leading analysis - Jammu Links News
How does Allogene Therapeutics Inc. compare to its industry peersMaximize your portfolio’s growth potential - Jammu Links News
Is it the right time to buy Allogene Therapeutics Inc. stockJaw-dropping returns - Jammu Links News
Is Allogene Therapeutics Inc. stock overvalued or undervaluedMaximize returns with disciplined investment techniques - Jammu Links News
What drives Allogene Therapeutics Inc. stock priceStrong return on assets - Jammu Links News
What are Allogene Therapeutics Inc. company’s key revenue driversUnstoppable profit momentum - Jammu Links News
How many analysts rate Allogene Therapeutics Inc. as a “Buy”Access daily stock market expert updates - Jammu Links News
What is the dividend policy of Allogene Therapeutics Inc. stockGet real-time alerts on high-potential stocks - Jammu Links News
What are the latest earnings results for Allogene Therapeutics Inc.Jaw-dropping returns - Jammu Links News
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):